AR102782A1 - Composición farmacéutica, su preparación y sus usos - Google Patents

Composición farmacéutica, su preparación y sus usos

Info

Publication number
AR102782A1
AR102782A1 ARP150103850A ARP150103850A AR102782A1 AR 102782 A1 AR102782 A1 AR 102782A1 AR P150103850 A ARP150103850 A AR P150103850A AR P150103850 A ARP150103850 A AR P150103850A AR 102782 A1 AR102782 A1 AR 102782A1
Authority
AR
Argentina
Prior art keywords
nanoparticle
pharmaceutical
carrier
biocompatible
subject
Prior art date
Application number
ARP150103850A
Other languages
English (en)
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of AR102782A1 publication Critical patent/AR102782A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica que comprende la combinación de (i) al menos una nanopartícula biocompatible y de (ii) al menos un portador que comprende al menos un compuesto farmacéutico, para administrar a un sujeto que necesita de tal compuesto farmacéutico, en donde la combinación de la al menos una nanopartícula biocompatible y del al menos un portador que comprende los compuestos farmacéuticos potencia la eficacia de los compuestos de interés. La dimensión más larga de la nanopartícula biocompatible está típicamente entre aproximadamente 4 y aproximadamente 500 nm y su valor de carga en superficie absoluto es de al menos 10 mV (|10 mV|). El portador carece, además, de cualquier agente estéricamente estabilizante de superficie. Composición para usar para la administración de los compuestos farmacéuticos en un sujeto que lo necesita, en donde la al menos una nanopartícula biocompatible y el al menos un portador que comprende el al menos un compuesto farmacéutico se han de administrar por separado en un sujeto que necesita de dicho compuesto farmacéutico, típicamente entre más de 5 minutos y aproximadamente 72 horas entre sí. Reivindicación 4: La composición farmacéutica de acuerdo con la reivindicación 3, en donde la nanopartícula se selecciona de una nanopartícula a base de lípidos, una nanopartícula a base de proteínas, una nanopartícula a base de polímero, una nanopartícula a base de copolímero, una nanopartícula a base de carbono y una nanopartícula de tipo viral.
ARP150103850A 2014-11-25 2015-11-24 Composición farmacéutica, su preparación y sus usos AR102782A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14306875 2014-11-25

Publications (1)

Publication Number Publication Date
AR102782A1 true AR102782A1 (es) 2017-03-22

Family

ID=52013982

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103850A AR102782A1 (es) 2014-11-25 2015-11-24 Composición farmacéutica, su preparación y sus usos

Country Status (24)

Country Link
US (1) US10765632B2 (es)
EP (2) EP4431155A2 (es)
JP (1) JP6789960B2 (es)
KR (1) KR102666251B1 (es)
CN (1) CN107106703A (es)
AR (1) AR102782A1 (es)
AU (1) AU2015352685B2 (es)
BR (1) BR112017010953B1 (es)
CA (1) CA2968919C (es)
DK (1) DK3236934T3 (es)
EA (1) EA201791147A1 (es)
ES (1) ES2982895T3 (es)
FI (1) FI3236934T3 (es)
HK (1) HK1245085A1 (es)
IL (2) IL290114B1 (es)
LT (1) LT3236934T (es)
MX (2) MX2017006812A (es)
NZ (1) NZ769187A (es)
PL (1) PL3236934T3 (es)
PT (1) PT3236934T (es)
SG (1) SG11201704219UA (es)
TW (1) TW201628656A (es)
UA (1) UA123665C2 (es)
WO (1) WO2016083333A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509436TA (en) 2013-05-30 2015-12-30 Nanobiotix Pharmaceutical composition, preparation and uses thereof
JP6836510B2 (ja) 2014-11-25 2021-03-03 キュラディグム・エスアエスCuradigm Sas 少なくとも2つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用
WO2016083331A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
HUE056175T2 (hu) 2014-11-25 2022-01-28 Curadigm Sas Gyógyászati készítmények, elõállításuk és alkalmazásaik
EP3302419A1 (en) 2015-05-28 2018-04-11 Nanobiotix Nanoparticles for use as a therapeutic vaccine

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
CN1756533B (zh) * 2002-12-31 2010-06-16 Bsv研究及开发私人有限公司 非聚乙二醇化的长期循环的脂质体
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
JP2007523090A (ja) * 2004-02-10 2007-08-16 バーンズ−ジューイッシュ ホスピタル デコイ系を用いたターゲティングされた微粒子剤の有効性および安全性の改善方法
US20060264804A1 (en) * 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
US20070088414A1 (en) * 2005-05-25 2007-04-19 Campbell Robert L Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
JP2009536151A (ja) 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
JP2009536162A (ja) 2006-05-04 2009-10-08 ユニバーシティー オブ サウス オーストラリア ナノ粒子被覆カプセルからの薬物放出
CN101795671A (zh) * 2007-08-21 2010-08-04 阿尔扎公司 用于体内施用硼酸化合物的脂质体组合物
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
WO2009081287A2 (en) 2007-12-21 2009-07-02 University Of Guelph Polysaccharide nanoparticles
CA2716347C (en) 2008-02-21 2017-06-20 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
WO2010048623A2 (en) 2008-10-26 2010-04-29 Board Of Regents, The University Of Texas Systems Medical and imaging nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
CN102781472B (zh) 2010-02-17 2014-07-02 国立大学法人神户大学 放射线治疗剂
KR101786142B1 (ko) 2010-03-26 2017-10-17 아브락시스 바이오사이언스, 엘엘씨 간세포 암종의 치료 방법
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
JP5713311B2 (ja) 2010-09-24 2015-05-07 国立大学法人名古屋大学 リポソーム複合体、その製造方法、及びその使用
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
WO2012104277A2 (en) * 2011-01-31 2012-08-09 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
CN103429227B (zh) 2011-01-31 2017-12-19 纳米生物技术公司 纳米粒子递送系统、其制备及应用
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
US20150209397A1 (en) 2012-09-07 2015-07-30 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
SG11201509436TA (en) * 2013-05-30 2015-12-30 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
WO2016083331A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
JP6836510B2 (ja) 2014-11-25 2021-03-03 キュラディグム・エスアエスCuradigm Sas 少なくとも2つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用
CA2968473A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
HUE056175T2 (hu) 2014-11-25 2022-01-28 Curadigm Sas Gyógyászati készítmények, elõállításuk és alkalmazásaik

Also Published As

Publication number Publication date
BR112017010953A2 (pt) 2018-02-14
FI3236934T3 (fi) 2024-07-22
IL290114A (en) 2022-03-01
ES2982895T3 (es) 2024-10-18
AU2015352685A1 (en) 2017-07-13
IL252462B (en) 2022-03-01
PT3236934T (pt) 2024-08-01
BR112017010953B1 (pt) 2024-01-16
US10765632B2 (en) 2020-09-08
EP4431155A2 (en) 2024-09-18
SG11201704219UA (en) 2017-06-29
IL290114B1 (en) 2024-11-01
NZ732995A (en) 2021-01-29
EP3236934B1 (en) 2024-05-22
US20170258721A1 (en) 2017-09-14
KR102666251B1 (ko) 2024-05-27
CA2968919C (en) 2023-07-18
CN107106703A (zh) 2017-08-29
IL252462A0 (en) 2017-07-31
MX2017006812A (es) 2018-02-12
PL3236934T3 (pl) 2024-10-28
LT3236934T (lt) 2024-08-26
CA2968919A1 (en) 2016-06-02
EA201791147A1 (ru) 2017-11-30
MX2021010595A (es) 2021-09-23
TW201628656A (zh) 2016-08-16
JP6789960B2 (ja) 2020-11-25
DK3236934T3 (da) 2024-08-19
JP2017538783A (ja) 2017-12-28
NZ769187A (en) 2023-07-28
KR20170093860A (ko) 2017-08-16
UA123665C2 (uk) 2021-05-12
WO2016083333A1 (en) 2016-06-02
EP3236934A1 (en) 2017-11-01
AU2015352685B2 (en) 2020-09-17
HK1245085A1 (zh) 2018-08-24

Similar Documents

Publication Publication Date Title
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
AR102782A1 (es) Composición farmacéutica, su preparación y sus usos
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
CL2016001547A1 (es) Composiciones para el cuidado oral
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
CL2016001509A1 (es) Formas cristalinas de los análogos de sofosbuvir antivirales
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY36665A (es) Derivados de ciclohexano sustituidos con amidas
AR079890A1 (es) Estabilizacion de peliculas de oxido de zinc en composiciones bucales
AR094583A1 (es) Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizante y métodos para elaborar y usar los mismos
GT201400043A (es) Imidazopiridazinas sustituidas con amino
AR102779A1 (es) Composición farmacéutica, su preparación y sus usos
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
CU20150071A7 (es) Composición de liberación demorada que comprende biguanida
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
NI201500096A (es) Compuesto químicos
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
CL2016002389A1 (es) Compuestos derivados de amidopiridina, agonista inverso del receptor cannabinoide tipo 2 composicion farmaceutica procedimiento de preparación y uso de los compuestos en el tratamiento o profilaxis del dolor neuropatico, asma, osteoporosis, inflamacion, entre otros.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
MX2017006148A (es) Composiciones para el cuidado personal con dos fases beneficas.
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.

Legal Events

Date Code Title Description
FB Suspension of granting procedure